Turn Therapeutics (NASDAQ:TTRX) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on the company. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. WBB Securities upgraded shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price objective on the stock in a report on Friday, October 23rd. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Finally, LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Turn Therapeutics Price Performance

TTRX opened at $10.43 on Friday. The company has a fifty day moving average price of $11.72 and a two-hundred day moving average price of $7.01. The firm has a market capitalization of $318.43 million and a PE ratio of -35.97. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $16.45. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current year.

Institutional Trading of Turn Therapeutics

A number of institutional investors have recently made changes to their positions in TTRX. SteelPeak Wealth LLC grew its position in Turn Therapeutics by 0.7% in the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after purchasing an additional 1,819 shares in the last quarter. Ieq Capital LLC acquired a new stake in Turn Therapeutics in the 2nd quarter valued at $1,660,000. BlackRock Inc. bought a new stake in Turn Therapeutics during the 2nd quarter worth about $282,000. Bridgewater Advisors Inc. bought a new stake in Turn Therapeutics during the 2nd quarter worth about $242,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics during the 2nd quarter worth about $119,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.